(Total Views: 582)
Posted On: 09/22/2020 2:44:39 AM
Post# of 154115
Re: ClosetInvestor #57253
It was just a suggestion... people will ask anything they like obviously...
I don't feel like COVID-19 trial design has been covered at all, e.g. for what effect size trial was powered; what consequences admission of SOC will have etc.. These are the tough questions.
Without doing that, it is impossible to assess chances of success properly.
For instance, had we known that 50% mild, even with 0-1 symptom score were enrolled in CD-10, we'd have known that PE was unachievable.
Re: cancer... Data has to mature. We need CTC CAML..., better PFS and OS data, on 30-40 patients on 700mg for both mTNBC and basket trial to draw meaningful conclusions IMO.
I don't feel like COVID-19 trial design has been covered at all, e.g. for what effect size trial was powered; what consequences admission of SOC will have etc.. These are the tough questions.
Without doing that, it is impossible to assess chances of success properly.
For instance, had we known that 50% mild, even with 0-1 symptom score were enrolled in CD-10, we'd have known that PE was unachievable.
Re: cancer... Data has to mature. We need CTC CAML..., better PFS and OS data, on 30-40 patients on 700mg for both mTNBC and basket trial to draw meaningful conclusions IMO.
(4)
(0)
